Ranolazine dihydrochloride

Ranolazine dihydrochloride Basic information
Product Name:Ranolazine dihydrochloride
Synonyms:(+/-)-4-[2-HYDROXY-3-(O-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETO-2',6'-XYLIDIDE DIHYDROCHLORIDE;n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride;(+/-)-N-(2,6-DIMETHYLPHENYL)-4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETAMIDE DIHYDROCHLORIDE;RANOLAZINE DIHYDROCHLORIDE;RANOLAZINE HCL;Ranolazine DiHCI;Ranolazine and salt;N-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)-propyl)piperazin-1-yl)acetamide di
CAS:95635-56-6
MF:C24H35Cl2N3O4
MW:500.46
EINECS:
Product Categories:Active Pharmaceutical Ingredients;Cardiovascular APIs;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Ranolazine;Aromatics Compounds;Pharmaceuticals
Mol File:95635-56-6.mol
Ranolazine dihydrochloride Structure
Ranolazine dihydrochloride Chemical Properties
Melting point 222-229.5 °C(lit.)
storage temp. Desiccate at RT
solubility H2O: 10 mg/mL, soluble
form solid
color off-white
Merck 14,8111
Stability:Hygroscopic
CAS DataBase Reference95635-56-6(CAS DataBase Reference)
Safety Information
Safety Statements 22-24/25
WGK Germany 3
RTECS TK7845370
HS Code 29335990
MSDS Information
ProviderLanguage
SigmaAldrich English
Ranolazine dihydrochloride Usage And Synthesis
DescriptionRanolazine is a piperazine derivative with cardioprotective activity. It reduces the late sodium current (INa) in mouse myocytes expressing the long QT syndrome 3 mutant sodium channel DKPQ, ventricular myocytes isolated from a canine model of heart failure, guinea pig ventricular myocytes exposed to hydrogen peroxide or anemone toxin-II, and HEK293 cells expressing human Nav1.5 channels (IC50s = 5.9-15 μM) as well as the late potassium current (IKr) in canine ventricular myocytes and HEK293 cells (IC50s = 11.5 and 14.4 μM, respectively). Ranolazine also inhibits radioligand binding to α1-, β1-, and β2-adrenergic receptors (Kis = 8.2-19.5, 1.4-8.6, and 0.5-14.8 μM, respectively). In vivo, ranolazine (480 μg/kg per min) reduces clofilium-induced prolongation of the QTc interval and Torsade de Pointes (TdP) in rabbits. Ranolazine also reduces interstitial collagen deposition as well as atrial natriuretic peptide (ANP; Item Nos. 24539 | 24276), connective tissue growth factor (CTGF), brain natriuretic peptide (BNP; ), and matrix metalloproteinase-2 (MMP-2) mRNA levels, and prevents left ventricular dilation in a mouse model of cardiotoxicity induced by doxorubicin .
Chemical PropertiesWhite Crystalline Powder
Usestreatment of angina and congestive heart failure
UsesRanolazine Dihydrochloride is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.
Biological ActivityAntianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late I Na and I Kr currents.
Biochem/physiol ActionsRanolazine is a derivative of anti-ischemic piperazine and acts as sodium (Na+)-current inhibitor. It has the potential to treat diastolic heart failure and helps in ameliorating myocardial diastolic function.
storageDesiccate at RT
Ranolazine dihydrochloride Preparation Products And Raw materials
Glycyrrhizic acid Capecitabine THIFLUZAMIDE Zolmitriptan Tenofovir Promethazine hydrochloride Propyl gallate Chlorpromazine hydrochloride Methoxyammonium chloride Acetamide Ranolazine Cetirizine hydrochloride Dihydrochloride Thioacetamide Ranolazine dihydrochloride Propyl butyrate N,N-Dimethylacetamide CHLOROPHOSPHONAZO III

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.